Keefe Bruyette analyst Paul Johnson lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15.50 from $17 and keeps an Outperform rating on the shares. The risks are more than discounted into the stock price at this point, although credit issues have not fully inflected, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCAP:
- Crescent Capital BDC price target lowered to $14 from $15 at Wells Fargo
- Crescent Capital BDC Reports Q3 2025 Earnings
- Crescent Capital BDC, Inc. Earnings Call Insights
- Crescent Capital BDC price target lowered to $15.50 from $16.50 at Clear Street
- Crescent Capital BDC reports Q3 EPS 46c, consensus 46c